Related Experiment Video
Updated: Apr 28, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Enhanced lung cancer cell inhibition using thymol nano-formulation: Design, physicochemical profiling, cytotoxic
Yang Xue1, Peirui Chen1, Mupeng Li1
1Department of Cardio-Thoracic Surgery, Deyang People's Hospital, Deyang, Sichuan, 618000, China.
Abstract:
Lung cancer is one of the most prevalent and deadly malignancies globally, characterized by high mortality rates, frequent metastasis, and the development of resistance to conventional therapies. These challenges underscore the urgent need for novel and effective treatment strategies. Utilizing nano-formulation to enhance the delivery of hydrophobic, natural bioactive compounds is a promising approach to improve their aqueous solubility, bioavailability, and targeted therapeutic efficacy. This study developed a stable thymol nano-formulation (ThNF) using Tween-80, yielding monodisperse particles of 22.64 ± 1.47 nm with excellent long-term stability. The ThNF exhibited significantly enhanced in vitro anticancer activity against A549 lung carcinoma cells compared to free thymol, demonstrated by a lower IC50 value (38.87 μM vs. 53.59 μM), stronger time- and dose-dependent cytotoxicity, and a superior ability to inhibit metastatic behaviours like cell migration and clonogenic survival. Mechanistic investigation through computational studies revealed that thymol has a strong binding affinity for two established and effective targets in lung cancer pathogenesis: PKBα/Akt and VPS34/PI3K, with binding energies of -6.0 and -6.2 kcal/mol, respectively. Molecular dynamics simulations and MM-PBSA free energy calculations confirmed the stability of these complexes, which are primarily stabilized by van der Waals interactions. These findings collectively demonstrate that the nano-formulation strategy successfully elavates the anticancer activity of thymol, and its interaction with key oncogenic proteins PKBα and VPS34 provides preliminary evidence for its dual-target mechanism for lung cancer therapy.
Insights
A novel thymol nano-formulation (ThNF) shows enhanced anticancer effects against lung cancer cells. This nanotechnology improves thymol delivery and efficacy, targeting key proteins for potential new therapies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Pharmacology
Background:
- Lung cancer presents significant global health challenges due to high mortality, metastasis, and treatment resistance.
- Novel therapeutic strategies are urgently needed to overcome these limitations.
- Nano-formulation offers a promising approach to enhance the delivery and efficacy of hydrophobic natural compounds.
Purpose of the Study:
- To develop a stable thymol nano-formulation (ThNF) for improved lung cancer treatment.
- To evaluate the in vitro anticancer activity and metastatic inhibition of ThNF.
- To investigate the molecular mechanisms underlying ThNF's therapeutic effects.
Main Methods:
- Development of a stable thymol nano-formulation (ThNF) using Tween-80.
- In vitro assessment of ThNF's cytotoxicity, migration, and clonogenic survival inhibition against A549 lung carcinoma cells.
- Computational studies including molecular docking, molecular dynamics simulations, and MM-PBSA to analyze interactions with PKBα/Akt and VPS34/PI3K.
Main Results:
- ThNF produced monodisperse nanoparticles (22.64 ± 1.47 nm) with excellent stability.
- ThNF demonstrated significantly enhanced in vitro anticancer activity and reduced IC50 compared to free thymol.
- ThNF effectively inhibited lung cancer cell migration and clonogenic survival.
- Computational analysis revealed strong binding affinities of thymol to PKBα/Akt and VPS34/PI3K, with stable complex formation.
Conclusions:
- Nano-formulation significantly enhances the anticancer efficacy of thymol against lung cancer cells.
- Thymol's dual-target interaction with PKBα and VPS34 provides a potential mechanism for its therapeutic action.
- ThNF represents a promising strategy for developing novel lung cancer therapies.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023